Comparative serum and sebum concentrations and efficacy of orally administered conventional itraconazole 100 mg twice daily vs conventional itraconazole 200 mg once daily vs super bioavailable itraconazole 130 mg once daily vs super bioavailable itraconazole 100 mg once daily in subjects with Dermatophytosis.

Scarlet Clinic0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年5月2日

试验速览

暂无简介。

•1.Subject able to understand and ready to provide written informed consent.
•2.Males and females aged >=18 years, clinically diagnosis for tinea corporis or tinea cruris with clinical score >=5.
•3.Consent of the participating subject to provide photography of the affected area before, during and after the study.

•1.Subjects not having tinea corporis or tinea cruris infection.
•2.Subjects who received any oral or topical tinea treatments, within one week prior to screening or had ingested any drug in the week prior to start or during the treatment, which in the opinion of investigator could compromise the study.
•3. Subjects with history of hypersensitivity to study drug, immunocompromised status or superadded bacterial infection.
•4. Pregnant or lactating women.
•5. Subjects with a serious illness (e.g. diabetes mellitus, collagen diseases, auto-immune diseases, hematological diseases and malignant tumors); and, those with liver dysfunction, kidney dysfunction or cardiac problems.
•6.Subjects who received an investigational drug or have participated in a clinical trial within the previous 30 days.
•7.Subject has history of drug dependence or excessive alcohol intake on a habitual basis.

发起方

Scarlet Clinic